184 related articles for article (PubMed ID: 24788571)
21. Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey--GALATA study.
Ayvaz G; Keskin L; Akin F; Dokmetas HS; Tasan E; Ar IB; Uren E;
Curr Med Res Opin; 2015 Apr; 31(4):623-32. PubMed ID: 25697921
[TBL] [Abstract][Full Text] [Related]
22. The efficacy of vildagliptin concomitant with insulin therapy in type 2 diabetic subjects.
Ito D; Inoue K; Kaneko K; Yanagisawa M; Sumita T; Ikegami Y; Awata T; Ishida H; Katayama S; Inukai K
J Clin Med Res; 2015 May; 7(5):303-7. PubMed ID: 25780477
[TBL] [Abstract][Full Text] [Related]
23. Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.
Montilla S; Marchesini G; Sammarco A; Trotta MP; Siviero PD; Tomino C; Melchiorri D; Pani L;
Nutr Metab Cardiovasc Dis; 2014 Dec; 24(12):1346-53. PubMed ID: 25300980
[TBL] [Abstract][Full Text] [Related]
24. Safety and effectiveness of non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta-analysis.
Gray LJ; Dales J; Brady EM; Khunti K; Hanif W; Davies MJ
Diabetes Obes Metab; 2015 Jul; 17(7):639-48. PubMed ID: 25777247
[TBL] [Abstract][Full Text] [Related]
25. Review of empagliflozin monotherapy for previously untreated patients with type 2 diabetes mellitus: Comparison with sitagliptin.
Cornell S
Postgrad Med; 2015 Apr; 127(3):277-81. PubMed ID: 25724655
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes.
Ohmura H; Mita T; Taneda Y; Sugawara M; Funayama H; Matsuoka J; Watada H; Daida H;
J Clin Med Res; 2015 Apr; 7(4):211-9. PubMed ID: 25699116
[TBL] [Abstract][Full Text] [Related]
27. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.
Scheen AJ
Expert Opin Drug Saf; 2015 Apr; 14(4):505-24. PubMed ID: 25630605
[TBL] [Abstract][Full Text] [Related]
28. Diabetes-related quality measure attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trials.
Bailey RA; Vijapurkar U; Meininger GE; Rupnow MF; Blonde L
Am J Manag Care; 2014 Dec; 20(13 Suppl):s296-305. PubMed ID: 25734218
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of saxagliptin as add-on therapy in type 2 diabetes.
Neumiller JJ
Clin Diabetes; 2014 Oct; 32(4):170-7. PubMed ID: 25646943
[TBL] [Abstract][Full Text] [Related]
30. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
[TBL] [Abstract][Full Text] [Related]
32. Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study.
Fu AZ; Johnston SS; Ghannam A; Tsai K; Cappell K; Fowler R; Riehle E; Cole AL; Kalsekar I; Sheehan J
Diabetes Care; 2016 May; 39(5):726-34. PubMed ID: 26740636
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of Cardiovascular Injury in Type 2 Diabetes and Potential Effects of Dipeptidyl Peptidase-4 Inhibition.
Dokken B
J Cardiovasc Nurs; 2016; 31(3):274-83. PubMed ID: 25829138
[TBL] [Abstract][Full Text] [Related]
34. Beneficial Effects of Vildagliptin on Metabolic Parameters in Patients with Type 2 Diabetes.
Shimodaira M; Niwa T; Nakajima K; Kobayashi M
Endocr Metab Immune Disord Drug Targets; 2015; 15(3):223-8. PubMed ID: 25809193
[TBL] [Abstract][Full Text] [Related]
35. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Zannad F; Cannon CP; Cushman WC; Bakris GL; Menon V; Perez AT; Fleck PR; Mehta CR; Kupfer S; Wilson C; Lam H; White WB;
Lancet; 2015 May; 385(9982):2067-76. PubMed ID: 25765696
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: A multinational 24-week, randomized clinical trial.
Wang W; Yang J; Yang G; Gong Y; Patel S; Zhang C; Izumoto T; Ning G
J Diabetes; 2016 Mar; 8(2):229-37. PubMed ID: 25753488
[TBL] [Abstract][Full Text] [Related]
37. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials.
Monami M; Dicembrini I; Mannucci E
Nutr Metab Cardiovasc Dis; 2014 Jul; 24(7):689-97. PubMed ID: 24793580
[TBL] [Abstract][Full Text] [Related]
38. Testing the therapeutic equivalence of alogliptin, linagliptin, saxagliptin, sitagliptin or vildagliptin as monotherapy or in combination with metformin in patients with type 2 diabetes.
Messori A; Fadda V; Maratea D; Trippoli S; Marinai C
Diabetes Ther; 2014 Jun; 5(1):341-4. PubMed ID: 24793219
[TBL] [Abstract][Full Text] [Related]
39. Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: The ODYSSEE observational study.
Valensi P; de Pouvourville G; Benard N; Chanut-Vogel C; Kempf C; Eymard E; Moisan C; Dallongeville J
Diabetes Metab; 2015 Jun; 41(3):231-8. PubMed ID: 25976701
[TBL] [Abstract][Full Text] [Related]
40. Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes.
Katzeff HL; Williams-Herman D; Xu L; Golm GT; Wang H; Dong Q; Johnson JR; O'Neill EA; Kaufman KD; Engel SS; Goldstein BJ
Curr Med Res Opin; 2015 Jun; 31(6):1071-7. PubMed ID: 25850968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
